
Drugmaker Indivior must face a lawsuit by 42 state attorneys general accusing it of using illegal tactics to shield its opioid addiction treatment Suboxone from generic competition, a federal judge has ruled.
US District Judge Mitchell Goldberg in Philadelphia found Monday that a reasonable jury could find that Indivior’s switch from a pill to an oral film form of the drug in 2009 was intended to extend its monopoly just as generic manufacturers were poised to begin selling their own pills, a strategy known as product hopping. He denied the Virginia-based company’s motion for a judgment in its favor.
States have said that the company’s conduct forced consumers to pay inflated prices for the treatment amid an epidemic of opioid addiction.
“The cost of critical medication must not be inflated through anticompetitive tactics,” Wisconsin Attorney General Josh Kaul, who is leading the multistate coalition, said in a statement.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Dollar Tree to Sell Family Dollar for $1 Billion, Ending Struggling Merger
Mar 26, 2025 by
CPI
Meta Platforms Defends Use of Authors’ Works in AI Training in US Court
Mar 26, 2025 by
CPI
EU Pressed Meta to Address Antitrust Concerns Over Facebook Marketplace
Mar 26, 2025 by
CPI
UBS, Nomura, and UniCredit Fail to Overturn EU Antitrust Fines in Bond Trading Cartel Case
Mar 26, 2025 by
CPI
Coca-Cola Among Firms Targeted in EU Antitrust Raids
Mar 26, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mobile Ecosystems
Mar 24, 2025 by
CPI
Mobile Ecosystems: An Intellectual Entelechy but A Necessary Model
Mar 24, 2025 by
Alba Ribera Martinez
Creating Contestability and Fairness in Mobile Ecosystems: The Contribution of the DMA
Mar 24, 2025 by
Damien Geradin & Daniel Mandrescu
Digital Ecosystems and the Not (Yet) As Efficient Competitor Principle
Mar 24, 2025 by
Thomas Hoppner & Philipp Westerhoff
Assessing the Competition Law Scrutiny of Smart Wearables and Mobile AR/VR Devices
Mar 24, 2025 by
Kayvan Hazemi-Jebelli